CTOs on the Move

Unity Biotechnology

www.unitybiotechnology.com

 
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY`s initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Daren Wilkinson
Senior Director IT Infrastructure Profile
Matthew Park
Senior Director, Information Technology Profile

Funding

Unity Biotechnology raised $116M on 10/27/2016
Unity Biotechnology raised $35M on 08/17/2017
Unity Biotechnology raised $55M on 03/19/2018

Similar Companies

Sony Biotechnology Inc

iCyt is a profitable, innovative, bioscience technology company that will contribute to its community by: delivering novel cell measurement and handling technologies that enable our clients to create important new healthcare and agriculture

Neurotech Pharmaceuticals

Neurotech Pharmaceuticals, Inc. is a Lincoln, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TCR2

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.

ReproSource

ReproSource is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Camurus

Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal® technology and extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX.